Five dihydrochalcone derivatives, 2'-carboxymethoxy-4, 4'-bis (3-methyl-2-butenyloxy) dihydrochalcone (M-6-b), 2', 4-bis (carboxymethoxy)-4'-(3-methyl-2-butenyloxy) dihydrochalcone (M-2), 2', 4-bis (carboxymethoxy)-4'-(3-carboxy-2-butenyloxy) dihydrochalcone (M-1-a), 2', 4-bis (carboxymethoxy)-4'-(3-hydroxymethyl-2-butenyloxy) dihydrochalcone (M-1-b), and 2'-carboxymethoxy-4-hydroxy-4'-(3-methyl-2-butenyloxy) dihydrochalcone (M-4-b), which are the main metabolites in rats of a new anti-ulcer drug "sofalcone"(2'-carboxymethoxy-4, 4'-bis (3-methyl-2-butenyloxy) chalcone) were synthesized and the anti-ulcer activities of the major metabolites in humans, M-6-b, M-2, and M-1-a, were examined by Shay's and Takagi's methods and also by the use of rats with histamine-induced ulcer. The most active compound was M-6-b, which showed activity equal to or slightly weaker than that of sofalcone.
No takes yet. Share an insight, caveat, or question.
HATAYAMA et al. (1985) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: